BARD1 and pancreatic neuroendocrine neoplasm: Although the susceptibility to PDAC and pancreatic NEN in patients with rare germline mutations in BARD1 remains to be studied, familial inheritance patterns and research evidence suggest that BARD1 may disrupt HR as mutations in BRCA2 and other DDR genes have also been shown to be tumorigenic.